Lower TIGIT/LAG-3 binding affinities of these antibodies compared to their benchmarks could also prevent them from inducing ADCC/ADCP of effector T cells while maintaining their potency in promoting T cell activation and cancer cell killing. Here, LAG3 is linked to cancer.